Janus 激酶抑制剂巴瑞替尼不是治疗 COVID-19 的理想选择。
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
机构信息
Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, 600117, Chennai, India.
Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, India.
出版信息
Int J Antimicrob Agents. 2020 May;55(5):105967. doi: 10.1016/j.ijantimicag.2020.105967. Epub 2020 Apr 4.
Abstract
The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.
摘要
自 2019 年 12 月以来，武汉新型冠状病毒感染疫情一直是全球关注的焦点。此次感染已成为全球性大流行。了解病原体的病毒学特性并探索这种大流行的治疗选择非常重要。正在考虑重新利用药物来治疗 COVID-19。在已确定的药物中，巴利昔替尼因其能够通过阻止克拉里丁相关内吞作用来抑制病毒组装而成为研究人员关注的焦点。我们试图探讨为什么巴利昔替尼不是治疗 COVID-19 的理想选择。
相似文献
1
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.Janus 激酶抑制剂巴瑞替尼不是治疗 COVID-19 的理想选择。
Int J Antimicrob Agents. 2020 May;55(5):105967. doi: 10.1016/j.ijantimicag.2020.105967. Epub 2020 Apr 4.
2
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
3
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.抑制 JAK 酶治疗 SARS-CoV-2？JAK 抑制剂在 COVID-19 治疗中的潜在作用。
Sci Immunol. 2020 May 8;5(47). doi: 10.1126/sciimmunol.abc5367.
4
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.巴瑞替尼，一种具有潜在作用的药物，可以阻止 SARS-COV-2 进入靶细胞，并控制由 COVID-19 引起的细胞因子风暴。
Int Immunopharmacol. 2020 Sep;86:106749. doi: 10.1016/j.intimp.2020.106749. Epub 2020 Jul 1.
5
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.巴利昔替尼的作用机制支持人工智能预测在 COVID-19 患者中的检测。
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
6
Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects.巴瑞替尼治疗肥胖而非消瘦 COVID-19 肺炎患者的显著疗效。
RMD Open. 2024 May 24;10(2):e004045. doi: 10.1136/rmdopen-2023-004045.
7
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.巴利昔替尼作为 COVID-19 患者对沙利鲁单抗无完全应答的补救治疗。
Infection. 2020 Oct;48(5):767-771. doi: 10.1007/s15010-020-01476-7. Epub 2020 Jul 8.
8
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.巴瑞替尼：关于COVID-19的药理学、安全性及新出现临床经验的综述
Pharmacotherapy. 2020 Aug;40(8):843-856. doi: 10.1002/phar.2438. Epub 2020 Jul 27.
9
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.生物制剂治疗的风湿性疾病合并冠状病毒感染的推荐建议。
J Autoimmun. 2020 May;109:102442. doi: 10.1016/j.jaut.2020.102442. Epub 2020 Apr 2.
10
COVID-19: an unexpected indication for anti-rheumatic therapies?新冠病毒肺炎：抗风湿治疗的意外指征？
Rheumatology (Oxford). 2020 Jun 1;59(6):1200-1203. doi: 10.1093/rheumatology/keaa194.
引用本文的文献
1
Examining efficacy and safety of ethyl acetate extract from as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial.考察[具体植物名称]乙酸乙酯提取物作为COVID-19辅助疗法的疗效和安全性：一项随机、多中心、对照临床试验。 （注：原文中“as complementary therapy in COVID-19”前缺少具体植物名称，翻译时添加了[具体植物名称]以保证句子完整通顺）
Avicenna J Phytomed. 2024 Nov-Dec;14(6):699-710. doi: 10.22038/AJP.2024.24523.
2
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
3
Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.当前JAK激酶抑制剂作为抗新冠病毒药物的治疗意义：综述
Front Pharmacol. 2023 Mar 20;14:1135145. doi: 10.3389/fphar.2023.1135145. eCollection 2023.
4
Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases.靶向人类蛋白的抗病毒药物发现和再利用研究：以蛋白激酶为重点。
Viruses. 2023 Feb 19;15(2):568. doi: 10.3390/v15020568.
5
Adverse effect signature extraction and prediction for drugs treating COVID-19.治疗新冠肺炎药物的不良反应特征提取与预测
Front Genet. 2022 Nov 4;13:1019940. doi: 10.3389/fgene.2022.1019940. eCollection 2022.
6
Identification of key molecules in COVID-19 patients significantly correlated with clinical outcomes by analyzing transcriptomic data.通过分析转录组数据鉴定与 COVID-19 患者临床结局显著相关的关键分子。
Front Immunol. 2022 Aug 22;13:930866. doi: 10.3389/fimmu.2022.930866. eCollection 2022.
7
Recent clinical findings on the role of kinase inhibitors in COVID-19 management.近期关于激酶抑制剂在 COVID-19 管理中作用的临床发现。
Life Sci. 2022 Oct 1;306:120809. doi: 10.1016/j.lfs.2022.120809. Epub 2022 Jul 13.
8
Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs.新冠疫情期间的酶：对人体影响、酶市场及新药前景的概述。
Med Res Rev. 2022 Nov;42(6):2126-2167. doi: 10.1002/med.21919. Epub 2022 Jun 28.
9
Can anti-parasitic drugs help control COVID-19?抗寄生虫药物能帮助控制新冠病毒吗？
Future Virol. 2022 Mar. doi: 10.2217/fvl-2021-0160. Epub 2022 Mar 18.
10
Current challenges in different approaches to control COVID-19: a comprehensive review.控制新冠病毒的不同方法中的当前挑战：一项全面综述
Bull Natl Res Cent. 2022;46(1):47. doi: 10.1186/s42269-022-00730-2. Epub 2022 Mar 3.
本文引用的文献
1
Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review.新型冠状病毒肺炎感染的影像学表现：放射学发现与文献综述
Radiol Cardiothorac Imaging. 2020 Feb 13;2(1):e200034. doi: 10.1148/ryct.2020200034. eCollection 2020 Feb.
2
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
3
COVID-19: combining antiviral and anti-inflammatory treatments.2019冠状病毒病：联合抗病毒与抗炎治疗
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
4
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.评估巴瑞替尼治疗类风湿关节炎临床试验中的乙型肝炎病毒。
RMD Open. 2020 Feb;6(1). doi: 10.1136/rmdopen-2019-001095.
5
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
6
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
7
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
8
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.将舒尼替尼和厄洛替尼重新用于登革热治疗的可行性和生物学原理。
Antiviral Res. 2018 Jul;155:67-75. doi: 10.1016/j.antiviral.2018.05.001. Epub 2018 May 16.
Zotero 插件